The Future of GLP-1 Medications: Pills, Triple Agonists, and What's Coming Next

Semaglutide and tirzepatide transformed the treatment of obesity and diabetes — but they are only the beginning. A remarkable wave of next-generation medications is arriving: pills instead of injections, drugs that hit two or three hormone targets at once, once-monthly shots, and combinations designed to preserve muscle while stripping away fat. Some are already FDA-approved; others are in late-stage testing.

This is the final chapter of our GLP-1 series, looking ahead. Here is an honest map of what's here, what's coming, and what it may mean for patients — with a clear distinction between approved treatments and those still under investigation.

Where We Are Now: The Current Benchmarks

To understand what's coming, start with today's approved options. Semaglutide (Ozempic, Wegovy) produces roughly 15% weight loss and carries the deepest evidence for heart, kidney, and liver protection. Tirzepatide (Mounjaro, Zepbound) — a dual GLP-1/GIP agonist — produces about 20%–21% and, in a head-to-head trial, outperformed semaglutide for weight loss (about 20% vs 14% at 72 weeks) (Aronne et al., New England Journal of Medicine, 2025).

These are excellent drugs, but they share limitations: most require weekly injections, they commonly cause gastrointestinal side effects, and some patients do not reach their goals. The next generation is being engineered specifically to address these gaps — better convenience, better tolerability, better body composition, and greater efficacy.

Oral GLP-1 Medications: The Injection-Free Future

For many people, the needle is the single biggest barrier. That is now changing.

Oral semaglutide 25 mg — a once-daily tablet — was FDA-approved in December 2025 for chronic weight management, bringing injectable-level efficacy into pill form. Its main catch is administration: it must be taken on an empty stomach with a small sip of water, waiting 30 minutes before eating or drinking (Novo Nordisk FDA labeling, 2025).

The bigger leap is orforglipron (brand name Foundayo), the first oral small-molecule, non-peptide GLP-1 receptor agonist — FDA-approved in April 2026 (FDA Orange Book, 2026). Unlike oral semaglutide, orforglipron is not a peptide, so it resists digestion, does not require refrigeration, and — importantly — can be taken with or without food. In the phase 3 ATTAIN-1 trial of more than 3,100 adults with obesity without diabetes, orforglipron 36 mg produced about 11.2% weight loss at 72 weeks, with over half of patients losing at least 10% (Wharton et al., New England Journal of Medicine, 2025). In ATTAIN-2, in people with type 2 diabetes, it produced meaningful weight loss plus improved blood sugar (Horn et al., Lancet, 2026).

The weight loss with orforglipron is somewhat less than injectable semaglutide or tirzepatide. But for the many people who will not accept an injection, an effective, food-flexible pill fundamentally changes the equation — and its simple manufacturing could improve global access.

Triple Agonists: Retatrutide

If tirzepatide's two-target approach was a leap, retatrutide may be the next. Retatrutide activates three receptors at once — GLP-1, GIP, and glucagon. The glucagon component is the novel piece: it can increase energy expenditure and help the liver burn fat, which is why retatrutide is being studied for both obesity and liver disease.

In a phase 2 trial published in the New England Journal of Medicine, retatrutide 12 mg produced up to 24.2% weight loss at 48 weeks — and the weight-loss curves had not yet plateaued (Jastreboff et al., New England Journal of Medicine, 2023). Strikingly, every participant at the higher doses lost at least 5% of their body weight, and about a quarter of those on the top dose lost 30% or more — a magnitude previously seen mainly with bariatric surgery. Phase 3 trials (the TRIUMPH program) are underway. If they confirm the phase 2 results, retatrutide could become the most effective weight-loss medication yet — but until then, it remains investigational.

Amylin Combinations: CagriSema and Amycretin

Amylin is a hormone released with insulin that promotes fullness and slows stomach emptying through pathways distinct from GLP-1 — making it a natural partner.

CagriSema is a once-weekly combination of semaglutide and the long-acting amylin analogue cagrilintide. In the phase 3 REDEFINE 1 trial of over 3,400 adults with obesity without diabetes, CagriSema produced about 20.4% weight loss at 68 weeks, versus roughly 15% with semaglutide alone and 3% with placebo (Garvey et al., New England Journal of Medicine, 2025). In REDEFINE 2, in people with type 2 diabetes, it produced about 13.7% weight loss with strong improvements in blood sugar (Davies et al., New England Journal of Medicine, 2025). A dedicated cardiovascular outcomes trial (REDEFINE 3) is running.

Amycretin takes a different route — a single molecule that activates both GLP-1 and amylin receptors. In an early phase 1b/2a study, the injectable form produced up to about 24.3% weight loss at 36 weeks, and an oral version produced meaningful loss in just 12 weeks (Dahl et al., Lancet, 2025). These are eye-catching numbers, but the study was small (125 participants), short, and had a high dropout rate — so larger, longer trials are needed before drawing conclusions.

MariTide: Once-Monthly Dosing

MariTide (maridebart cafraglutide) is engineered for convenience. It combines GLP-1 receptor activation with GIP receptor blockade in a long-acting molecule with a half-life around three weeks — potentially allowing once-monthly or even less frequent dosing. Early trial data showed weight loss in the mid-teens percentage range over a year, and phase 3 testing is ongoing (Gonzalez-Rellan and Drucker, JAMA, 2025). An intriguing scientific puzzle: both GIP stimulation (as in tirzepatide) and GIP blockade (as in MariTide) appear to aid weight loss when paired with GLP-1 — and why remains an active research question. For people who struggle with weekly injections, a monthly option could meaningfully improve adherence.

Muscle-Preserving Combinations

As covered in the muscle chapter, the next frontier is not just losing more weight — it's losing better weight. Experimental drugs that block myostatin and activin (natural brakes on muscle growth), such as bimagrumab, apitegromab, and trevogrumab, are being combined with GLP-1 drugs to preserve lean mass. In early trials, these combinations preserved a far greater share of muscle while keeping fat loss high (Gonzalez-Rellan and Drucker, JAMA, 2025). They remain in phase 2, but they point toward a future where weight loss is more precisely "fat-targeted."

Expanding Indications: Far Beyond Weight

The future is not only about new molecules — it's about new uses. Semaglutide is already FDA-approved not just for diabetes and obesity but for reducing cardiovascular risk, for chronic kidney disease, and for metabolic liver disease (MASH); tirzepatide is approved for obstructive sleep apnea (FDA Orange Book, 2026). Active research is exploring GLP-1 medications for heart failure, peripheral artery disease, Alzheimer's disease, alcohol use disorder, and inflammatory conditions — many of these covered in earlier chapters of this series. A recurring theme is that some benefits appear at least partly independent of weight loss, hinting that GLP-1 signaling has direct protective effects across many organs.

The Bottom Line

Medicine is in the middle of a metabolic revolution. Today's approved drugs — semaglutide and tirzepatide, now joined by oral options like orforglipron — already transformed care. What's coming could go further: triple agonists like retatrutide pushing toward surgical-level weight loss, amylin combinations like CagriSema and amycretin, once-monthly injections like MariTide, and muscle-preserving combinations that improve the quality of weight loss. The clear trajectory is toward greater efficacy, more convenience (pills and monthly shots), better tolerability, and protection spanning the heart, kidneys, liver, and brain. Many of these agents are still investigational, and results can change with larger trials — but the direction is unmistakable. If you're weighing your options, the practical takeaway is simple: more and better choices are on the way, and your physician can help you decide what fits you now and what may be worth waiting for.